凯赛生物: 第二届董事会第三十四次会议决议公告

Core Viewpoint - The board of Shanghai Kaisa Biotechnology Co., Ltd. held its 34th meeting on August 15, 2025, where several key resolutions were passed regarding the company's half-year report, fundraising usage, and stock incentive plans [1][2][3][4][5] Group 1: Board Meeting Details - The board meeting was legally convened with all 9 directors present, and it was chaired by Xiucai Liu [1] - The meeting adhered to the relevant laws and regulations, ensuring its validity [1] Group 2: Half-Year Report - The board approved the full and summary version of the 2025 half-year report, which complies with the disclosure regulations [2] - The voting results for this resolution were unanimous, with 9 votes in favor [2] Group 3: Fundraising Report - The board also approved a special report on the storage and usage of fundraising for the first half of 2025, in accordance with regulatory requirements [2] - This resolution also received unanimous support with 9 votes in favor [2] Group 4: Stock Incentive Plans - The board resolved to invalidate 136,430 shares from the 2020 stock incentive plan due to unmet performance conditions [3] - The voting results for this resolution were unanimous, with 9 votes in favor [3] Group 5: Adjustment of Stock Incentive Price - The board approved an adjustment of the grant price for the 2022 stock incentive plan from 56.45 yuan per share to 56.05 yuan per share [4] - This resolution received 8 votes in favor, with one director abstaining [4] Group 6: Additional Stock Incentive Invalidations - The board also invalidated 698,810 shares from the 2022 stock incentive plan due to unmet performance conditions [5] - This resolution received 8 votes in favor, with one director abstaining [5] Group 7: Performance Improvement Action Plan - The board approved the half-year evaluation report of the 2025 quality improvement and return action plan, which aims to enhance shareholder value [5] - This resolution received unanimous support with 9 votes in favor [5]